STERIS plc (STE) — Technical & Contextual Analysis Report

Analysis date: 2026-09-18 (latest verified trading session) | Exchange: NYQ | Sector: Health Care / Medical Devices

1. Executive Summary

STE is in a full bearish technical alignment — price is below the 10 EMA, 50 SMA, and 200 SMA simultaneously — following a ~13.9% decline from the early-August closing high (238.18 on 2026-08-10) to 205.04 on 2026-09-18. Momentum is at its weakest reading in the 60-day lookback (RSI 25.55), MACD has broken below zero and is still accelerating lower, and the most recent session printed the heaviest volume since mid-June (1,543,400 shares, ~2.4× the trailing 30-session average) on a down close. At the same time, price is now stretched into the Bollinger Lower Band zone (band at 200.32), which coincides with the May–June trough area (closes of 200.64 on 5/11 and 198.79 on 6/17) — a classic capitulation-vs-continuation decision zone. The external QuantOrb money-flow screen (MFI 8.33, "BUY" strength 0.8077 as of the 9/17 session) flags extreme oversold money flow, but that snapshot predates the 9/18 high-volume decline and is a screen output, not a recommendation. Fundamentals (FQ1'27: revenue +7%, adjusted EPS $2.59, guidance unchanged per the 2026-08-05 8-K) do not obviously explain the selloff, which argues the drawdown is technical/flow-driven — favoring patience and trigger-based entries over chasing either direction.

2. Price Action Structure (from retrieved OHLCV, verified against snapshot)

Phase 1 — Q1 correction (March): Steady decline from 246.28 (3/2) to a mid-March trough (211.08 on 3/12), then stabilization in the 214–222 range through April.

Phase 2 — Spring slide and June lows (late April–June): A second leg down took STE to the 200.64 close on 5/11 and the June trough at 198.79 (6/17 close, intraday low 197.41). This established the 197–201 zone as the visible low of the entire March–June window.

Phase 3 — Summer recovery (July–August): Rally from ~208 (7/8) to a closing high of 238.18 (8/10), with a secondary peak area 235–238 through 8/25. Note the extraordinary 8/6 session (open 213.89, low 213.89, high 231.07, close 231.07 — the day after the 8/5 earnings 8-K): a severe opening gap down followed by a full intraday recovery. This single session inflated ATR readings (peaking at 7.02 on 8/7) and is the largest one-day range in the dataset.

Phase 4 — September breakdown (current): After the $0.69 ex-dividend on 9/4, the stock rolled over: 228.95 (9/1) → 224.59 (9/4) → 218.44 (9/8) → a four-session slide to 210.76 (9/11), a one-day bounce (213.66 on 9/14), then four consecutive down closes: 210.28 → 209.90 → 208.04 → 205.04 (9/15–9/18). Eight of the last nine sessions were down closes.

Verified latest row (source of truth): Open 206.24 / High 207.70 / Low 205.00 / Close 205.04 / Volume 1,543,400.

3. Selected Indicators — Why These 8 and What They Say

I selected 8 complementary indicators covering four distinct analytical jobs — (a) trend regime on three horizons, (b) momentum direction and trigger timing, (c) mean-reversion stretch, and (d) volatility for risk control — while deliberately avoiding redundancy (e.g., MACD histogram duplicates MACD/Signal; Bollinger middle/upper duplicate the lower band plus MAs; VWMA overlaps the external MFI flow data).

3.1 close_10_ema — 213.13 (short-term trend trigger)

Price closed 8.09 points (−3.8%) below the 10 EMA. The EMA has declined for 10 straight sessions (232.96 on 9/1 → 213.13 on 9/18) with no pause. This is the fastest trend filter: no long setups are valid while price is below it, and a close back above ~213 is the first, cheapest momentum signal that sellers are losing control.

3.2 close_50_sma — 224.36 (medium-term trend / dynamic resistance)

Price is 19.32 points (−8.6%) below the 50 SMA. Critically, the 50 SMA peaked at 224.82 (9/10) and has now rolled over for six straight sessions (224.36 on 9/18) — the medium-term trend has just turned down after the summer repair attempt. Any rebound into 222.8–224.4 (Bollinger middle + 50 SMA confluence, see §5) should be treated as resistance, not support.

3.3 close_200_sma — 229.33 (long-term benchmark)

Price is 24.29 points (−10.6%) below the 200 SMA, which peaked on 8/21 (232.73) and is now declining (229.33 on 9/18) as June's lows drop out of the window. The 50 SMA remains ~5 points below the 200 SMA — the bearish MA configuration has persisted all summer and has not come close to repairing. Strategic context: STE is in a confirmed long-term downtrend until price reclaims ~229.

3.4 macd — −5.76 (momentum regime)

The MACD line peaked at +6.42 (8/11), crossed bearishly below its signal between 8/14 and 8/17, crossed the zero line between 9/4 (+0.55) and 9/8 (−0.45), and has since fallen for six consecutive sessions to −5.76. Lower price lows (210.76 → 209.90 → 208.04 → 205.04) are matched by lower MACD lows (−3.40 → −4.82 → −5.25 → −5.76): no bullish divergence exists yet — the downtrend is internally consistent.

3.5 macds — −3.49 (trigger line)

The signal line confirms and times the trend: MACD (−5.76) is 2.28 points below the signal (−3.49), i.e., bearish momentum is still widening, not decelerating. A crossover back above −3.49 is the concrete trigger to re-evaluate countertrend longs; until then, short-side or cash positioning has momentum confirmation.

3.6 rsi — 25.55 (oversold extremity / divergence watch)

RSI 25.55 is the lowest reading in the entire 60-day lookback (prior 60-day low was 27.10 on 9/11; the August range was roughly 47–68). Note the pattern: RSI hit 27.10 on 9/11, recovered to 33.06 on 9/14 with the price bounce, then made a lower RSI low (25.55) on a lower price close — bearish momentum persistence, not reversal. RSI < 30 warns against initiating fresh shorts at current levels (squeeze risk) but does not, by itself, constitute a buy signal in a confirmed downtrend.

3.7 boll_lb — 200.32 (mean-reversion stretch / capitulation zone)

Price closed four consecutive sessions below the lower band (9/8–9/11: 218.44 vs 222.33; 215.09 vs 218.92; 212.45 vs 215.40; 210.76 vs 212.09), a statistically extreme stretch, before re-entering the band on 9/14. The band has since declined to 200.32 while the middle band sits at 222.82 (upper 245.31) — price sits at roughly the 10th percentile of the band range (%B ≈ 0.11). The lower band now converges almost exactly with the May–June trough closes (200.64 on 5/11; 198.79 on 6/17) — a confluence decision zone at 197–200.5.

3.8 atr — 5.08 (volatility / risk management)

ATR has cooled from its 8/7 earnings-shock peak (7.02) but remains elevated (5.08 ≈ 2.5% of price vs ~4.5–5 typical in April). Practical use: with ATR at ~5.1, a standard 1.5–2.0× ATR stop is ~7.6–10.2 points; the 9/18 session itself ranged 2.70 points with a close near the low — intraday follow-through risk is real, and position sizes should be calibrated down relative to calmer regimes.

4. Volume & Flow Context

• Distribution signal: The 9/18 volume of 1,543,400 is ~2.4× the trailing 30-session average (~655k, computed from the retrieved CSV rows 8/7–9/18) and the highest since 6/18 (1,599,100) — selling pressure is intensifying into the low, not fading.
• External money-flow screen (QuantOrb, per provided FACTS): MFI 8.33 with a BUY signal (strength 0.8077) as of the 2026-09-17 session — an extreme oversold money-flow reading. Caveat: this snapshot predates the 9/18 high-volume decline, so the true current MFI is likely at or below that level; and a quantitative screen output is explicitly not a recommendation. It is best used as corroborating evidence of oversold stretch, alongside RSI and the Bollinger breach history.
• Institutional positioning (13F-HR, as of 2026-03-31, per provided source): Orbis Allan Gray +15.3%, Generation IM +10.5%, Select Equity Group +11.2% share adds, with only Copeland trimming (−3.8%). Directionally supportive of the "quality name in a technical downdraft" framing — though this snapshot is >5 months stale and subject to the 13F lag.

5. Fundamental Cross-Reference (per provided SEC documents)

The 2026-08-05 8-K (FQ1'27, ended 6/30/26) showed revenue +7% to $1.5B, constant-currency organic growth +6%, GAAP EPS $2.04 (vs $1.79), adjusted EPS $2.59 (vs $2.34), and unchanged full-year guidance, with management citing share gains in consumables/services and solid capital-equipment orders, plus a targeted restructuring around a new North Carolina Formulated Chemistries Center. There is nothing in this release that would predict a −10.4% September (9/1 close 228.95 → 9/18 close 205.04) — reinforcing that the breakdown is technical/flow-driven. That matters for positioning: fundamental deterioration is not confirmed, so aggressive shorting into oversold extremes carries headline/squeeze risk, while longs gain a "buy the dislocation" argument only after technical triggers fire. (Next quarterly report date is not in the provided documents; the prior fiscal Q1 report landed 2026-08-05.)

6. Confluence Level Map (all levels from verified/tool data)

7. Actionable Scenarios

A. Trend continuation (bearish, momentum-confirmed): Price below all three MAs, MACD below zero and widening, 50 SMA newly rolling over. Condition: a close below 200.32 (lower band / trough-zone confluence) on above-average volume opens the 197.4–198.8 June-trough reference and, if broken, uncharted territory relative to the March–June window. Invalidation: close back above 213.13 (10 EMA). Risk note: RSI 25.55 argues against initiating shorts here — await a weak bounce (e.g., rejection at 208–213) rather than shorting the hole.

B. Mean-reversion long (countertrend, trigger-dependent): The 4-session band breach (9/8–9/11) plus extreme RSI/MFI readings create a reversion setup, but nothing has triggered yet — MACD histogram is still widening (−2.28) and no RSI divergence exists. Trigger conditions: (1) MACD histogram contracts for 2+ sessions, (2) RSI turns up from below 30, and (3) a close back above ~208 (the 9/15–9/17 closing cluster). Targets: 213.13 (10 EMA) first, 222.8–224.4 (middle band + 50 SMA confluence) stretched. Stop: below 200 (clears band and trough zone), ≈1.5–2× ATR risk per share.

C. Cash / wait: Given full bearish alignment but oversold extremes, the highest-expectancy action for most accounts is waiting at the 197–200.5 decision zone for either a reversal trigger (Scenario B) or a breakdown confirmation (Scenario A).

Sizing: At ATR 5.08 (~2.5%/day), a 10-point stop on a $205 position is ~4.9% price risk — size positions so that this equals ≤1% of account equity (roughly ≤20% normal position size, or half that if trading the countertrend scenario).

8. Data Integrity & Caveats

• Discrepancy check: All indicator values from get_indicators (10 EMA 213.13, 50 SMA 224.36, 200 SMA 229.33, RSI 25.55, Bollinger lower 200.32, MACD −5.76, signal −3.49, ATR 5.08) match the verified snapshot exactly; MACD histogram −2.28 is consistent with MACD − signal. No discrepancies to flag.
• The 8/6 session (O 213.89 / H 231.07 / L 213.89 / C 231.07, the day after the earnings 8-K) is an unusually extreme range as reported by the vendor; it materially shaped August ATR values.
• The QuantOrb MFI snapshot (9/17) predates the 9/18 session; treat its "BUY" as a stale oversold screen flag, not a trade signal.
• No historical support/resistance bounces or future moves are claimed above; all references are to observed levels with concrete dates and prices.

9. Summary Table

Bottom line: STE is a technically confirmed downtrend trading at statistically stretched oversold levels directly above a major confluence support zone (197.4–200.6). Let the zone decide: a volume-backed break of 200.32 extends the downtrend, while a trigger-confirmed hold sets up a reversion trade toward the 213 (10 EMA) and 222.8–224.4 (middle band/50 SMA) supply shelf. Until one of those fires, cash is a position.

Overall Sentiment: Mildly Bullish (Score: 5.9/10) Confidence: Low

STE (STERIS plc, NYSE) — Sentiment Report, 2026-09-11 to 2026-09-18

1. Source-by-source breakdown

News (Yahoo Finance; 2 items in window) — mildly bullish, low conviction. Both items are screener-style commentary rather than event-driven news; no hard catalysts (ratings actions, guidance changes, M&A, litigation, FDA news) surfaced for STE in the window. [price target withheld — AdCho policy] - Barchart — "STERIS Stock: Is STE Underperforming the Healthcare Sector?": the more STE-specific framing — STE "has trailed the broader market over the past year, while Wall Street analysts remain cautiously optimistic." One item simultaneously acknowledges relative weakness and analyst support: constructive, but not committal.

StockTwits (0 messages) — silent. The $STE cashtag feed returned no messages in the window, so no bullish/bearish ratio can be computed. There is no retail euphoria (contrarian over-extension risk) and no capitulation chatter; STE is simply not on retail's radar this week. This is primarily a data limitation and is the main reason confidence is rated low.

Reddit/X feed (4 posts in window of 13 fetched; 7 token-spam excluded) — thin, slightly bearish. The feed delivered an X (Twitter) recent-search, not posts from r/wallstreetbets, r/stocks or r/investing; no genuine subreddit discussion of $STE appeared. Of the 4 posts, 2 are follow-promo spam (@iMausamDeen, "turned $2,200 into $47,000… follow @CecileAnna_") with no substantive STE content and are excluded from weighting. The two remaining items are both mildly bearish: - @_TP888 (2026-09-15): "A single buyer took the $STE offer down. $125K in puts. 210.00 strike, Oct 16." — the only substantive directional social signal in the window: a single $125K put block, 210 strike, Oct 16 expiry. - @StockAlertGov (2026-09-14): disclosure alert that Rep. April McClain Delaney (D) SOLD $STE in the $100,001–$250,000 band (traded Aug 25, disclosed ~15 days later). Modest size and a long lag — a negative optic rather than an informative flow signal. - Engagement on all four posts was effectively nil (0 likes, 0 reposts, single-digit to low-hundreds impressions), so none of this validates as broadening sentiment.

Context documents (outside the sentiment window, cited for framing): - QuantOrb money-flow engine (2026-09-17 US session): MFI 8.33 — deep in conventional oversold territory (<20) after persistent net selling; engine signal BUY at strength 0.8077. A quantitative screen output, not a recommendation — but it corroborates the Barchart underperformance narrative and reframes it as stretched downside momentum rather than fresh deterioration. - 8-K, Q1 FY2027 (2026-08-05): revenue +7% to $1.5B; constant-currency organic +6%; adjusted diluted EPS $2.59 vs $2.34 (+10.7%); reported EPS $2.04 vs $1.79. CEO Dan Carestio cites "stable underlying demand," share gains in consumables and services, and "solid order growth for capital equipment"; FY27 revenue and EPS expectations unchanged. A targeted restructuring tied to a new Formulated Chemistries Center of Excellence in North Carolina was also announced. Fundamentals are intact and support the analysts' cautious optimism. - 13F-HR snapshot (positions as of 2026-03-31; stale by up to ~2 quarters; only 5 tracked filers, non-exhaustive): three meaningful adds — Orbis Allan Gray +343,401 shares (+15.3%), Generation IM +219,976 (+10.5%), Select Equity Group +215,346 (+11.2%); one flat (Diker +0.1%); one small trim (Copeland −6,763, −3.8%). Net accumulation tilt among tracked holders. - 10-K (filed 2026-05-29): three-segment infection-prevention franchise (Healthcare, AST, Life Sciences) post-Dental divestiture — context for the durability of the consumables/services engine the 8-K highlights; no new information in the window.

2. Cross-source divergences and alignments

• Alignment: Barchart's "trailed the broader market" ↔ QuantOrb MFI 8.33. The underperformance narrative and the oversold technical reading describe the same condition; the BUY flag at 0.8077 strength suggests the market is treating recent weakness as overextended rather than fundamentals-driven — consistent with the August 8-K's unchanged guidance.
• Alignment: sell-side optimism (StockStory/Barchart) ↔ institutional accumulation tilt in the 13F snapshot. The professional community is net constructive across both lenses, albeit on stale, small-sample data.
• Divergence: social/X flow (one put block, one congressional sale) leans bearish while news and quant lean constructive. The bearish social evidence comprises exactly two low-reach datapoints — too thin to constitute a counter-trend; it registers as a bearish undercurrent worth monitoring (Oct 16 expiry), not a directional driver.
• Divergence within fundamentals: a strong Q1 print (+7% revenue, +10.7% adjusted EPS, guidance intact) coexists with 12-month relative underperformance — the market is discounting the fundamental trajectory, which is precisely the setup an oversold mean-reversion screen keys on.

3. Dominant narrative themes

1. A quality healthcare laggard analysts won't give up on — both news items frame STE as underperforming yet favored, with targets implying upside; "cautiously optimistic" is the operative phrase.
2. Oversold technical condition — MFI 8.33 with a high-strength BUY screen output is the sharpest quantitative signal in the dataset.
3. Stable fundamental engine — consumables/services share gains and capital-equipment order growth; guidance unchanged despite a "complex operating environment."
4. Quiet tape, bearish whispers — zero retail chatter, one notable put block, one congressional sale: negative signals that currently lack breadth or engagement.

4. Catalysts and risks

Catalysts: - Next earnings (Q2 FY2027): the August 8-K confirms the quarterly cadence; a specific date is not stated in the provided documents. An in-line-to-better print against a depressed, oversold tape is the bullish scenario the quant screen implies. - 2026-10-16: expiry of the $210 puts flagged on X — a dated reference point for the bearish options positioning; covering/unwinding into expiry is a mechanical flow to watch. - Analyst target revisions following the StockStory "favorite stocks" grouping could act as a sentiment catalyst in either direction.

Risks: - Oversold can stay oversold: Barchart's framing is a 12-month relative trend, not a one-week dip; a money-flow BUY screen does not halt a sector-relative de-rating. - The put buyer may have a catalyst in view that is not visible in the provided sources; the flow is unverifiable beyond a single low-reach post. - Restructuring execution: the targeted plan tied to the North Carolina Formulated Chemistries Center of Excellence (announced with Q1) carries cost/execution optics risk. - Data-quality risk dominates this read: zero StockTwits coverage, spam-heavy social feed, only two generic news items, and a quarter-stale 5-filer 13F sample. Sentiment here is low-reliability and should be weighed alongside fundamentals and technicals, not alone.

5. Summary of key sentiment signals

Bottom line: a mildly bullish tilt — analyst constructiveness, intact Q1 FY2027 fundamentals, net institutional adds, and an oversold BUY screen — capped by thin, slightly bearish social flow and a persistent 12-month underperformance trend. The band would flip toward Mixed if the put-flow narrative broadens or picks up engagement. Confidence is low because two of the three sentiment channels were effectively silent or spam-filtered this week.

STE (STERIS plc) — Weekly News, Macro & Trading Analysis

Analysis date: 2026-09-18 | Ticker: STE (NYSE) | Sector: Health Care — Health Care Equipment / Medical Devices

1. Executive Summary

STERIS plc (STE) enters the week of 2026-09-18 as a fundamentally solid but rate-pressured defensive name showing signs of technical oversold exhaustion. The QuantOrb money-flow engine logged an MFI of 8.33 (deeply oversold) with a BUY signal at 0.8077 strength for the 2026-09-17 session — a classic mean-reversion setup. However, the dominant macro force right now is a bond market selloff: the 10-year Treasury yield touched 5.01% on 2026-09-16 (highest in the one-year window) before easing to 4.94%, while CPI has re-accelerated to ~3.0% YoY. This combination explains why STE has underperformed the broader market over the past year (per Barchart) despite healthy company fundamentals — a pattern that persists until long yields stabilize.

Net stance: Constructive medium-term (strong FY2027 Q1 print, unchanged guidance, institutional accumulation, solid macro demand backdrop), but tactically cautious — the 10Y at ~5% is a direct valuation headwind for long-duration med-tech equities. A staged entry or waiting for rate stabilization is the higher-probability path.

2. Company-Specific News (STE, 2026-09-11 → 2026-09-18)

The past week's STE-specific news flow was light but directionally informative:

1. [price target withheld — AdCho policy] The article itself carries the standard caveat that sell-side ratings skew bullish. → Sentiment tailwind, but with an embedded skepticism warning.

2. Barchart: "STERIS Stock: Is STE Underperforming the Healthcare Sector?" — Explicitly states STE has trailed the broader market over the past year, with analysts "cautiously optimistic." → This underperformance is consistent with the macro picture below: a defensive, bond-proxy-like med-tech compounder getting compressed by a ~83bp rise in the 10-year yield over the trailing year.

No company-specific negative catalysts, downgrades, litigation, or regulatory actions surfaced in the past week. The news vacuum around the stock, combined with an oversold MFI reading, suggests the underperformance is macro-driven (rates), not idiosyncratic deterioration.

3. Fundamental & Positioning Context (Source Documents)

FY2027 Q1 results (8-K, filed 2026-08-05) — the most recent hard financial data: - Revenue +7% to $1.5B; constant-currency organic growth +6% - GAAP diluted EPS $2.04 (vs. $1.79); adjusted EPS $2.59 (vs. $2.34, +10.7%) - CEO Dan Carestio: Healthcare segment driving growth, share gains in consumables and services, solid capital equipment order growth; full-year guidance unchanged - Targeted restructuring announced for a new Formulated Chemistries Center of Excellence in North Carolina

10-K (filed 2026-05-29): Three reportable segments — Healthcare, AST (Applied Sterilization Technologies), Life Sciences — following the FY2025 Dental divestiture. The recurring-revenue mix (consumables + services + outsourced reprocessing) is the core defensive characteristic.

13F positioning (as of 2026-03-31, subject to reporting lag): Net accumulation among tracked filers — - Orbis Allan Gray +15.3% (to 2,592,912 sh) - Select Equity Group +11.2% (to 2,143,379 sh) - Generation Investment Management +10.5% (to 2,308,459 sh) - Diker Management +0.1%; Copeland Capital -3.8% (to 168,908 sh)

Read-through: quality-focused institutions were adding into the period of weakness — a supportive, though lagged, signal.

QuantOrb technicals (2026-09-17 session): MFI 8.33 (extreme oversold territory, below the conventional 20 oversold line), BUY signal, strength 0.8077. This is a quantitative screen output, not a recommendation — but statistically, MFI readings this low in large-cap healthcare names have historically marked short-term capitulation zones.

4. Macro Backdrop (FRED Data, as of 2026-09-18)

Rates — the key headwind

Interpretation: The front end is anchored (Fed on hold), but the long end is selling off hard — the 10Y rose from 4.79% on 9/1 to above 5.00% by 9/15–9/16 before a partial retracement. The curve is flattening from the long end (bear flattening), implying rising term premium / inflation-uncertainty pricing rather than growth fears. For STE, a ~5% risk-free rate raises the discount rate on its long-duration, recurring-revenue cash flows — this is the single most direct explanation for the stock's trailing underperformance. The 9/17 pullback to 4.94% is the first crack in the move; confirmation requires several days below ~4.90%.

Inflation — re-accelerating

• CPI (CPIAUCSL): 334.131 (Aug 2026), ≈ +3.0% YoY vs. Sep 2025. Monthly path: a June dip (−0.4% m/m) was followed by +0.1% m/m in July and +0.4% m/m in August — a clear re-acceleration into the fall.
• This explains the Fed's hold at 3.63% and the long-end selloff. Softer inflation prints are the main macro trigger that would relieve pressure on STE's multiple.

Growth & labor — solid

• Unemployment: 4.1% (Aug 2026), steadily down from 4.4% a year ago. No labor-market deterioration.
• Solid employment supports hospital utilization, surgical procedure volumes, and capital budgets — the demand engines for STE's Healthcare segment and AST. This is the fundamental reason the 8-K could report "stable underlying demand" and strong capital equipment orders.

Volatility — orderly

• VIX: 15.44 (9/17), down from mid-month spikes of 17.84 (9/10) and 17.71 (9/16). Range-bound 14–18 for the year.
• No stress regime; equity drawdowns in names like STE are being driven by rates/rotation, not systemic risk. Low VIX also means hedging is cheap for traders who want downside protection while holding oversold defensive names.

5. Global News Flow (Past Week) — Low Signal

The global feed was dominated by micro/noise items: a Janus Henderson ETF launch, gold/silver drill results (Americas Gold & Silver), sugar prices undercut by demand concerns (two separate Barchart items — a mild, isolated soft-demand datapoint in ag commodities, not a broad consumer-demand signal), and Boeing/Starliner/Starliner-related stories (NASA exploring new missions with the troubled spacecraft; analysis on whether a faster factory can lift Boeing stock).

Takeaway: No systemic macro shock, geopolitical escalation, or sector-wide healthcare event in the past week's feed. The absence of negative global news reinforces the view that STE's weakness is a rates story, not a fundamentals or exogenous-crisis story.

6. Prediction Markets — Unavailable for This Date

Prediction-market odds (Fed decision, recession probability, sector events) were withheld for 2026-09-18: Polymarket serves only live odds on open markets with no historical vintage, so serving them would inject post-2026-09-18 information into this analysis. No market-implied probabilities are cited in this report. As a qualitative substitute: the Fed's hold at 3.63% for four straight months amid re-accelerating CPI (FRED data above) suggests near-term cut expectations should be treated with caution until a soft inflation print arrives.

7. Actionable Insights & Risk Scenarios

For STE-focused traders:

1. Mean-reversion setup with a rate caveat. MFI 8.33 + BUY (0.8077 strength) on 9/17, with no negative company news in the past week, favors a tactical bounce attempt. But a 10Y above 5% caps how far med-tech multiples can re-rate. Prefer staged entries over full positioning; adding is best justified if the 10Y holds below ~4.90–4.95%.

2. The trade is "rates, not the company." STE's trailing underperformance (Barchart) maps almost perfectly to the +83bp 1-year rise in the 10Y. The highest-conviction catalyst is a softer CPI print (the August figure re-accelerated +0.4% m/m) or any dovish shift from the Fed's hold at 3.63%. Until then, expect chop.

3. Fundamental floor is intact. FY2027 Q1: +7% revenue, +6% organic, adjusted EPS $2.59 (+10.7%), guidance unchanged, capital equipment orders solid (8-K). Institutions added 10–15% to positions into Q1-end (13F). Downside from here is more likely multiple compression than estimate cuts.

4. Curve watch: the 10Y−2Y at +0.25% and flattening fast. Still positive — no recession signal — but if it inverts via further long-end selloff, defensive healthcare would face both a growth scare and higher discount rates simultaneously. That's the scenario that breaks the bounce thesis.

5. Risk framing: With VIX ~15, protective puts/collars on any bounce-entry are inexpensive. Key events to monitor: the next CPI release, the next FOMC decision (Fed currently on hold at 3.63%), and STE's next earnings release (next scheduled report would be FY2027 Q2, following the 8/5 Q1 8-K).

8. Summary Table

All figures above are drawn from tool outputs and the provided source documents as of the 2026-09-18 analysis date; no market-implied probabilities are included due to prediction-market data unavailability for this date.

STERIS plc (NYSE: STE) — Comprehensive Fundamental Analysis

Analysis date: 2026-09-18 | Fiscal year ends March 31 (FY2027 Q1 ended June 30, 2026)

1. Executive Summary

STERIS plc is a Dublin-headquartered, NYSE-listed global leader in infection-prevention products and services operating three segments (Healthcare, AST, Life Sciences) after divesting its Dental segment in FY2025. The fundamental picture is that of a high-quality, defensively-positioned compounder: FY2026 revenue of $5.94B (+8.7% YoY), net income of $782.3M (+28.2% YoY), record free cash flow of $972.4M (+25.0% YoY), and net leverage of only ~0.86x TTM normalized EBITDA. The most recent quarter (FY2027 Q1, reported via 8-K on 2026-08-05) showed revenue +7%, adjusted EPS +10.7% to $2.59, and unchanged full-year guidance. Watch items are a YoY decline in Q1 operating cash flow driven by working-capital timing (seasonal inventory build), upcoming restructuring charges tied to a new North Carolina Formulated Chemistries Center of Excellence, and a goodwill/intangible-heavy balance sheet (54% of assets). A quantitative money-flow screen (MFI 8.33, BUY signal strength 0.8077 as of the 2026-09-17 session) suggests an oversold technical setup, though it is not itself a recommendation.

2. Company Profile & Business Model (per FY2026 10-K, filed 2026-05-29)

• Identity: STERIS plc, Dublin, Ireland; NYSE: STE; Sector: Health Care; Industry: Health Care Equipment.
• Mission/positioning: "A leading global provider of products and services that support patient care with an emphasis on infection prevention."
• Revenue mix by offering:
• Consumables: detergents, endoscopy accessories, barrier products, instruments/tools — recurring, razor/razor-blade economics.
• Services: equipment installation/maintenance, microbial reduction of medical devices, instrument/scope repair, lab testing, outsourced reprocessing — sticky, contract-based.
• Capital equipment: sterilizers, surgical tables, automated endoscope reprocessors — cyclical, order-book driven.
• Connectivity: operating room integration solutions.
• Segments (post-Dental divestiture, FY2025): Healthcare; Applied Sterilization Technologies (AST); Life Sciences. Dental is presented in discontinued operations, cleaning up the ongoing earnings base.
• Structural takeaway: roughly two-thirds-plus of the model is consumables + services (recurring revenue), which supports the company's margin resilience and consistent pricing power commentary ("share gains in consumables and services are fueling our performance" — Q1 FY27 8-K).

3. Latest Quarter — Fiscal 2027 Q1 (ended June 30, 2026; 8-K filed 2026-08-05)

Key 8-K takeaways: - CEO Dan Carestio: results reflected "stable underlying demand," Healthcare segment driving growth via share gains in consumables and services, "solid order growth for capital equipment." - Guidance: revenue and earnings expectations for FY2027 are unchanged — a maintenance, not a raise, implying management sees no incremental macro tailwind or headwind worth revising. - Announced a targeted restructuring plan for a new Formulated Chemistries Center of Excellence in North Carolina → expect incremental restructuring charges in coming quarters (recent quarters' restructuring line was small: $0.0M in Q1 FY27; $2.2M in Q2 FY26). - The reported-vs-adjusted EPS gap of $0.55 in Q1 is consistent with the company's typical amortization/one-time add-back profile — monitor whether the restructuring increases this gap in FY27. - My vendor's income-statement data cross-validates the 8-K exactly (revenue $1,492.7M, net income $200.1M, diluted EPS $2.04).

4. Multi-Year Income Statement History (Annual)

Interpretation: - Clean earnings trajectory: Since exiting Dental (discontinued ops losses of -$173.2M in FY24, -$450.4M in FY23), continuing-ops EPS has compounded rapidly: $3.81 → $6.20 → $7.93 (FY26 +27.9% YoY). - Structural margin expansion: operating margin up ~180 bps over two years (16.8% → 18.6%), gross margin up ~100 bps — evidence of pricing power, mix shift toward services/consumables, and integration synergies. - Deleveraging dividend: interest expense fell from $144.4M (FY24) to $60.7M (FY26); EBIT/interest coverage improved from ~5.9x to ~18.3x. This is a major contributor to the EPS surge and continues into FY27 (Q1 net interest expense $12.7M vs $14.1M a year ago). - Rising tax rate (21.3% → 25.0%) is a modest headwind that management is absorbing while still growing EPS ~28%. - R&D at ~1.9% of revenue is steady and grew +8.3% YoY in Q1 FY27 — adequate reinvestment for a med-tech incumbent.

5. Quarterly Income Trend (last 5 quarters)

• Seasonality: March (Q4) is the seasonally strongest revenue quarter; June quarters step down sequentially — the -6.0% QoQ revenue move into Jun-26 is normal, not deterioration.
• YoY cadence is what matters and is improving: revenue +7.3% and every profit line growing double-digits in the latest quarter, with Q1 gross margin the highest of the five quarters shown.
• SG&A grew only +4.5% YoY in Q1 FY27 ($369.7M vs $353.8M) against +7.3% revenue — visible operating leverage.

6. Balance Sheet & Liquidity (as of June 30, 2026)

Key observations: - Fortress-lite leverage: Net debt of $1,411.3M against TTM normalized EBITDA of ~$1,643.0M = ~0.86x (vs ~0.94x on FY2026 full-year EBITDA). Net debt has fallen for four straight quarters ($1,623.5M → $1,411.3M, -13%) while cash has built from $279.7M to $482.3M. This is a dramatic improvement from FY2024 (net debt ~$3.0B) and gives ample M&A/dry-powder capacity. - Interest coverage (FY26 EBIT/interest) ~18.3x; investment-grade profile intact. - Goodwill + intangibles = 53.6% of total assets ($5,752.7M / $10,736.1M) — typical of a serial acquirer, but it means tangible book ($1.45B) is small; ROE (~11.3% on FY26 average equity) is understated by the intangible base, while ROE on tangible equity is extremely high. Impairment risk exists in a downturn but amortization is declining (other intangibles fell from $2.08B in FY23 to $1.56B at Jun-26 as legacy deal intangibles roll off). - Current debt rose to $279.0M (from $154.7M at Mar-26) — a maturity coming current; with $482.3M cash and ~$280M quarterly FCF, refinancing risk is minimal, but note interest payable of $17.1M reflects semi-annual coupon timing. - Inventory +12.5% YoY ($712.1M vs $641.2M) and receivables +7.0% YoY — growth-driven working capital investment; receivables also show a seasonal drop from the March quarter.

7. Cash Flow & Capital Allocation

Annual:

Quarterly (last 5):

Interpretation: - Cash generation is the core bull case: OCF has compounded from $756.9M (FY23) to $1,341.4M (FY26); FCF from $395.0M to $972.4M. FY26 FCF margin of 16.4% is best-in-class for the period. - Q1 FY27 OCF fell 12.6% YoY ($367.1M vs $420.0M) and FCF fell 14.3% ($279.6M vs $326.4M) — entirely a working-capital timing story: change in working capital was +$17.8M vs +$96.2M a year ago (-$78.4M swing), driven by a seasonal -$73.3M inventory build and smaller receivables release (+$90.0M vs +$119.2M). Net income actually grew +12.8%, and OCF/net income conversion remains a healthy ~183%. Not a red flag, but the YoY FCF decline is the one soft data point in an otherwise pristine report. - Buybacks accelerating: $115.5M in Q1 FY27 — the largest quarterly repurchase in the five-quarter window and ~40% of the entire FY26 program ($235.5M). TTM buybacks = $340.4M. Share count is down ~1.1% YoY (98.5M → 97.46M). - Dividend: ~$61.4M/quarter ≈ ~$0.63/share quarterly (~$2.52 annualized), a payout of only ~32% of FY26 diluted EPS of $7.93 — ample room for the historical ~9-10% annual growth (dividends paid +31.7% over FY23→FY26). - Total TTM shareholder returns (buybacks + dividends) = $587.4M ≈ 63% of TTM FCF ($925.6M) — sustainable, with the rest funding CapEx (~6% of revenue) and small bolt-ons ($16M business purchase in Q1 FY27). - FY26 investing outflows also included $134M of investment purchases; M&A has been deliberately modest post-Dental divestiture (FY25 included $814.6M sale-of-business proceeds used for $1.16B debt paydown).

8. Institutional Ownership (13F-HR, positions as of 2026-03-31 — subject to up-to-45-day statutory lag)

• The four tracked accumulators added a combined ~779K shares in the March 2026 quarter — meaningful accumulation by quality-growth and value-oriented shops (Orbis Allan Gray, Generation IM's sustainability mandate, Select Equity's quality-growth book) into the position. One small holder (Copeland) trimmed modestly. Note: this is a tracked subset, not exhaustive 13F coverage, and reflects positions two quarters before the analysis date.

9. Quant Money-Flow Context (as of 2026-09-17 US session)

• QuantOrb money-flow engine: MFI reading 8.33; signal: BUY; signal strength 0.8077 (Health Care / Health Care Equipment classification).
• An MFI of 8.33 sits deep in oversold territory (<20), and the high signal strength indicates a strong quantitative buy designation. This implies the stock has seen notable recent selling pressure into fundamentally strong results — a classic potential mean-reversion setup.
• Caveat: this is a quantitative screen output, not a recommendation, and MFI oversold readings can persist in downtrends; it should be layered against the fundamental strength documented above, not used standalone.

10. Valuation & Data Limitations

• The fundamentals vendor withheld point-in-time profile data (market cap, P/E, 52-week range) for 2026-09-18 (it only serves present-day 2026-09-21 values, which would inject look-ahead bias). [price target withheld — AdCho policy]
• Traders can compute multiples themselves using the following point-in-time TTM figures (four quarters through Jun-30-2026):
• TTM revenue: $6,037.6M | TTM net income: $805.0M | TTM normalized EBITDA: $1,643.0M
• TTM reported diluted EPS: $8.18 ($2.04 + $2.24 + $1.96 + $1.94); Q1 FY27 adjusted EPS was $2.59 (full-year adjusted run-rate not derivable from my data)
• Shares outstanding: 97,457,680; dividend ~$2.52/sh annualized
• Net debt: $1,411.3M (add to equity market cap for EV)
• On FY26 fundamentals, STERIS screens as a premium-quality med-tech franchise; whether the multiple is attractive depends on the prevailing quote, which the oversold MFI reading suggests may have reset lower.

11. Risks & Catalysts

Risks: 1. Restructuring charges ahead — the North Carolina Formulated Chemistries Center of Excellence plan announced 2026-08-05 will add charges in FY27; watch the adjusted-vs-reported EPS gap (already $0.55 in Q1). 2. Working capital / FCF optics — Q1 FCF -14.3% YoY on seasonal inventory build (-$73.3M); if inventory growth (now +12.5% YoY) outpaces revenue for a second quarter, that would warrant scrutiny. 3. Balance-sheet opacity — goodwill + intangibles at 53.6% of assets creates impairment sensitivity and depresses conventional book metrics. 4. Tax-rate drift — effective rate rose from 21.3% (FY24) to 25.0% (FY26) and the Q1 FY27 calc rate was 26.5%; further drift would nibble at EPS growth. 5. Capital-equipment cyclicality — the Healthcare segment's "solid order growth" is good today, but capital orders are the most economically sensitive piece of the model. 6. Current debt step-up — $279.0M current vs $154.7M last quarter; a maturity to manage (well-covered by cash).

Catalysts: 1. FY27 Q2 earnings (expected early November 2026) — first test of the maintained guidance and restructuring charge size. 2. Continued buyback acceleration — the $115.5M Q1 pace annualizes to ~4.7% of the current share count if sustained. 3. Further deleveraging — ~$280M/quarter FCF against only ~0.86x net leverage supports M&A capacity or larger repurchases. 4. Margin trajectory — Q1's 45.8% gross margin and 19.2% operating margin were the best of the last five quarters; continued mix shift toward consumables/services extends the FY23→FY26 margin-up trend. 5. Oversold technical reset (MFI 8.33) potentially converging with strong fundamentals.

12. Actionable Takeaways for Traders

1. Fundamental quality is unambiguous. Five consecutive quarters of double-digit YoY net income growth, +8.7% FY26 revenue, FCF +25% to a record $972.4M, leverage ~0.86x, and 18x interest coverage. This is a low-risk fundamental profile in a defensive sector.
2. The one soft spot is Q1 cash flow, and it looks seasonal, not structural. The -$78.4M working-capital swing explains the entire YoY OCF decline; conversion (OCF/NI ~183%) remains excellent. Watch Q2 for normalization.
3. Capital-return inflection is underway. Buybacks at $115.5M in Q1 (largest in five quarters) plus a ~32%-payout dividend with ~10% growth history — a growing tailwind to per-share compounding on a ~97.5M share base already shrinking ~1%/yr.
4. Institutional accumulation + oversold quant signal (13F adds of ~779K shares by top tracked holders as of Mar-26; MFI 8.33 BUY, strength 0.8077 as of Sep-17) suggest sentiment has lagged fundamentals — a setup traders may view favorably, with the caveat that these are lagging/quantitative indicators.
5. Position sizing around known event risk: the FY27 Q2 print will quantify restructuring charges and confirm whether the unchanged guidance embeds conservatism. Risk-aware entries would account for that event window.
6. For valuation work, use TTM EPS of $8.18 and TTM EBITDA of $1,643.0M (plus $1,411.3M net debt for EV) against the live quote — my tools deliberately do not supply the point-in-time price.

13. Key Points Summary Table

Note on data provenance: Quarterly/annual statements are from the vendor's fundamental-data tools (retrieved 2026-09-21; periods cut at fiscal period end, and the most recent period may post with a lag). The FY2026 10-K excerpt and FY2027 Q1 8-K press release are cited directly above. The vendor deliberately withheld market-cap/valuation data for the 2026-09-18 vintage to avoid look-ahead bias, so no price-dependent figures appear in this report.